Pulse Biosciences (NASDAQ:PLSE) Posts Earnings Results

Pulse Biosciences (NASDAQ:PLSE) announced its earnings results on Monday. The company reported ($0.27) EPS for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.05, Zacks reports.

Pulse Biosciences Price Performance

PLSE opened at $20.83 on Monday. The firm has a market capitalization of $1.42 billion, a price-to-earnings ratio of -19.29 and a beta of 1.63. The company’s 50 day simple moving average is $20.91 and its two-hundred day simple moving average is $17.55. Pulse Biosciences has a 1-year low of $12.56 and a 1-year high of $26.30.

Insider Activity

In related news, insider Kevin Patrick Danahy sold 5,000 shares of the stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $23.64, for a total value of $118,200.00. Following the completion of the sale, the insider owned 43,298 shares of the company’s stock, valued at approximately $1,023,564.72. This trade represents a 10.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold 85,000 shares of company stock valued at $1,994,400 in the last ninety days. 74.60% of the stock is owned by corporate insiders.

Institutional Trading of Pulse Biosciences

Large investors have recently added to or reduced their stakes in the stock. Tudor Investment Corp ET AL acquired a new stake in shares of Pulse Biosciences in the 4th quarter worth $382,000. Inspire Investing LLC boosted its position in shares of Pulse Biosciences by 33.4% during the 4th quarter. Inspire Investing LLC now owns 34,192 shares of the company’s stock valued at $469,000 after acquiring an additional 8,561 shares during the last quarter. California State Teachers Retirement System boosted its position in shares of Pulse Biosciences by 23.2% during the 4th quarter. California State Teachers Retirement System now owns 21,165 shares of the company’s stock valued at $291,000 after acquiring an additional 3,991 shares during the last quarter. Russell Investments Group Ltd. grew its holdings in shares of Pulse Biosciences by 13.8% in the fourth quarter. Russell Investments Group Ltd. now owns 5,106 shares of the company’s stock valued at $70,000 after purchasing an additional 619 shares during the period. Finally, ExodusPoint Capital Management LP grew its holdings in shares of Pulse Biosciences by 14.9% in the fourth quarter. ExodusPoint Capital Management LP now owns 25,122 shares of the company’s stock valued at $345,000 after purchasing an additional 3,258 shares during the period. 76.95% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently commented on PLSE shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pulse Biosciences in a research report on Tuesday, April 21st. Wall Street Zen upgraded Pulse Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, February 21st. Oppenheimer reaffirmed an “outperform” rating and set a $30.00 target price on shares of Pulse Biosciences in a research note on Friday, February 20th. Finally, Mizuho set a $30.00 target price on shares of Pulse Biosciences in a report on Friday, February 6th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $30.00.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.